This HTML5 document contains 132 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/kegg-compound/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/mixture/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/pubchem-substance/
n24http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n27http://www.rxlist.com/cgi/generic/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/national-drug-code-directory/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n30http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/chemspider/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01390/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01390
rdf:type
n3:Drug
n3:description
Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.
n3:dosage
n19:271B44B7-363D-11E5-9242-09173F13E4C5 n19:271B44B8-363D-11E5-9242-09173F13E4C5 n19:271B44AC-363D-11E5-9242-09173F13E4C5 n19:271B44AD-363D-11E5-9242-09173F13E4C5 n19:271B44AE-363D-11E5-9242-09173F13E4C5 n19:271B44AF-363D-11E5-9242-09173F13E4C5 n19:271B44B0-363D-11E5-9242-09173F13E4C5 n19:271B44B1-363D-11E5-9242-09173F13E4C5 n19:271B44B2-363D-11E5-9242-09173F13E4C5 n19:271B44B3-363D-11E5-9242-09173F13E4C5 n19:271B44B4-363D-11E5-9242-09173F13E4C5 n19:271B44B5-363D-11E5-9242-09173F13E4C5 n19:271B44B6-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.
owl:sameAs
n13:DB01390 n24:DB01390
dcterms:title
Sodium bicarbonate
adms:identifier
n7:C12603 n8:D01203 n9:DB01390 n10:32139 n11:8609 n15:516892 n16:46507049 n17:63739-460-21 n18:PA451375 n25:Sodium_bicarbonate
n3:mechanismOfAction
Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]
n3:packager
n4:271B4480-363D-11E5-9242-09173F13E4C5 n4:271B4482-363D-11E5-9242-09173F13E4C5 n4:271B447F-363D-11E5-9242-09173F13E4C5 n4:271B448D-363D-11E5-9242-09173F13E4C5 n4:271B448E-363D-11E5-9242-09173F13E4C5 n4:271B448B-363D-11E5-9242-09173F13E4C5 n4:271B448C-363D-11E5-9242-09173F13E4C5 n4:271B4491-363D-11E5-9242-09173F13E4C5 n4:271B4492-363D-11E5-9242-09173F13E4C5 n4:271B448F-363D-11E5-9242-09173F13E4C5 n4:271B4490-363D-11E5-9242-09173F13E4C5 n4:271B4485-363D-11E5-9242-09173F13E4C5 n4:271B4486-363D-11E5-9242-09173F13E4C5 n4:271B4483-363D-11E5-9242-09173F13E4C5 n4:271B4484-363D-11E5-9242-09173F13E4C5 n4:271B4489-363D-11E5-9242-09173F13E4C5 n4:271B448A-363D-11E5-9242-09173F13E4C5 n4:271B4487-363D-11E5-9242-09173F13E4C5 n4:271B4488-363D-11E5-9242-09173F13E4C5 n4:271B4481-363D-11E5-9242-09173F13E4C5 n4:271B4495-363D-11E5-9242-09173F13E4C5 n4:271B4496-363D-11E5-9242-09173F13E4C5 n4:271B4493-363D-11E5-9242-09173F13E4C5 n4:271B4494-363D-11E5-9242-09173F13E4C5 n4:271B4499-363D-11E5-9242-09173F13E4C5 n4:271B449A-363D-11E5-9242-09173F13E4C5 n4:271B4497-363D-11E5-9242-09173F13E4C5 n4:271B4498-363D-11E5-9242-09173F13E4C5
n3:synonym
e 500 Baking soda NaHCO3 Sodium hydrogen carbonate Sodium bicarbonate Bicarbonate of soda Natriumhydrogenkarbonat Carbonic acid monosodium salt e-500 Sodium acid carbonate Sodium hydrogencarbonate e500
n3:mixture
n21:271B447B-363D-11E5-9242-09173F13E4C5 n21:271B447C-363D-11E5-9242-09173F13E4C5 n21:271B4479-363D-11E5-9242-09173F13E4C5 n21:271B447A-363D-11E5-9242-09173F13E4C5 n21:271B4477-363D-11E5-9242-09173F13E4C5 n21:271B4478-363D-11E5-9242-09173F13E4C5 n21:271B447D-363D-11E5-9242-09173F13E4C5 n21:271B447E-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Alan B. Gancy, Rustom P. Poncha, "Production of low bulk density product from sodium bicarbonate by the use of an inert gas stream." U.S. Patent US3984527, issued August, 1922.
n28:hasConcept
n29:M0026757
foaf:page
n27:sodbic.htm n30:sodium-bicarbonate.html
n3:IUPAC-Name
n14:271B44BD-363D-11E5-9242-09173F13E4C5
n3:InChI
n14:271B44C3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n14:271B44C2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n14:271B44BF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n14:271B44C0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n14:271B44C1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n14:271B44BB-363D-11E5-9242-09173F13E4C5 n14:271B44D2-363D-11E5-9242-09173F13E4C5
n3:logP
n14:271B44B9-363D-11E5-9242-09173F13E4C5 n14:271B44BC-363D-11E5-9242-09173F13E4C5
n3:logS
n14:271B44BA-363D-11E5-9242-09173F13E4C5
n3:pKa
n14:271B44D4-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:B05CB04 n23:B05XA02
n3:H-Bond-Acceptor-Count
n14:271B44C9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n14:271B44CA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n14:271B44C4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n14:271B44C5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n14:271B44C7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n14:271B44C6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n14:271B44C8-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
144-55-8
n3:containedIn
n20:271B44A4-363D-11E5-9242-09173F13E4C5 n20:271B44A5-363D-11E5-9242-09173F13E4C5 n20:271B44A2-363D-11E5-9242-09173F13E4C5 n20:271B44A3-363D-11E5-9242-09173F13E4C5 n20:271B44A8-363D-11E5-9242-09173F13E4C5 n20:271B44A9-363D-11E5-9242-09173F13E4C5 n20:271B44A6-363D-11E5-9242-09173F13E4C5 n20:271B44A7-363D-11E5-9242-09173F13E4C5 n20:271B449C-363D-11E5-9242-09173F13E4C5 n20:271B449D-363D-11E5-9242-09173F13E4C5 n20:271B449B-363D-11E5-9242-09173F13E4C5 n20:271B44A0-363D-11E5-9242-09173F13E4C5 n20:271B44A1-363D-11E5-9242-09173F13E4C5 n20:271B449E-363D-11E5-9242-09173F13E4C5 n20:271B449F-363D-11E5-9242-09173F13E4C5 n20:271B44AA-363D-11E5-9242-09173F13E4C5 n20:271B44AB-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n14:271B44CE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n14:271B44D0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n14:271B44D1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n14:271B44D3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n14:271B44CD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n14:271B44CC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n14:271B44CF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n14:271B44BE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n14:271B44CB-363D-11E5-9242-09173F13E4C5